

News Release

Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer

PHILADELPHIA, REHOVOT, Israel (January 11, 2016) – Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the European Patent Office (EPO) has granted a patent allowance for patent application No. 08844596.0, relating to “Targeting microRNAs for the Treatment of Liver Cancer.” This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq: RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.

“This patent allowance further bolsters our leading intellectual property position in microRNA technology, providing us with additional opportunities to monetize this expanding core asset,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Previously published pre-clinical data in *Clinical Research*, a peer reviewed journal, supports the important role that miRs like miR-191 may play in the treatment of hepatocellular carcinoma, the most common form of liver cancer. Liver cancer is a life-limiting disease for which there are inadequate treatment options and, consequently, a poor prognosis. We look forward to the advancement of clinical studies in pursuit of microRNA targets as a potentially effective treatment for liver cancer.”

“We are particularly encouraged by the expanding role of microRNAs to fight various cancers. As with our recently announced sublicense with Mirna Therapeutics, we are in a strong position to leverage our extensive intellectual property position to help advance the development of new and effective cancer treatments while creating value from this growing asset,” added Mr. Berlin.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit www.rosettagx.com.

Rosetta Genomics Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta's future expectations, plans and prospects, including but not limited to statements with respect to Rosetta's potential to create value by leveraging its intellectual property position, Rosetta retaining rights to the relevant intellectual property to utilize specific microRNAs, as well as Rosetta helping to advance the development of new and effective cancer treatments constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the Securities and Exchange Commission (SEC). In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Rosetta Genomics Contact:

Ken Berlin, President & CEO
(609) 419-9003
investors@rosettagenomics.com

Rosetta Genomics Investor Contact:

LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

###